Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Will novel oral formulations change the management of inflammatory bowel disease?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Mometasone furoate nasal spray for the treatment of asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Lixisenatide for type 2 diabetes mellitus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Serotonin 2A receptor antagonists for treatment of schizophrenia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Hemoglobin A1c-levels and subsequent risk of depression in individuals with and without diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effects of Ketone Bodies on Brain Metabolism and Function in Neurodegenerative Diseases

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Discontinuation of diabetes medication in the 10 years before death: a nationwide register-based study: 21-25 September 2020.

    Publikation: KonferencebidragKonferenceabstrakt til konferenceForskningpeer review

  5. Mannose-Binding Lectin and Risk of Cardiovascular Events and Mortality in Type 2 Diabetes: A Danish Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
BI 1356, a xanthine-based DPP-4 inhibitor, has reached Phase III trials. The compound efficiently inhibits dipeptidyl peptidase 4 (DPP-4) in vitro and in vivo. In vivo GLP-1 levels increase to levels at or above the levels of other DPP-4 inhibitors. Preclinical trials suggest a once-daily administration of 5 mg to be efficient, long-lasting and without known side effects.
OriginalsprogEngelsk
TidsskriftExpert Opinion on Investigational Drugs
Vol/bind18
Udgave nummer6
Sider (fra-til)835-838
Antal sider4
ISSN1354-3784
DOI
StatusUdgivet - 2009

ID: 64965445